Global Gesagliflozin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Gesagliflozin market size was valued at US$ 30.87 million in 2025 and is forecast to a readjusted size of US$ 162 million by 2032 with a CAGR of 11.9% during review period.
In 2025, global Garsorasib production reached approximately 5000 units.Garsorasib Tablets (generic name: Garsorasib Tablets, trade name: Anfangning) is an independently developed oral small-molecule targeted antineoplastic drug in China for the treatment of KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), belonging to irreversible KRAS G12C inhibitors. Its mechanism of action is to specifically bind and lock the inactive conformation of the mutant KRAS protein, block the abnormal activation of the downstream MAPK signaling pathway, thereby inhibiting tumor cell proliferation and inducing tumor cell apoptosis. This product is a 200 mg yellow oval film-coated tablet, approved for marketing in China in November 2024. It is mainly indicated for adult patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have received at least one prior systemic therapy. It serves as an important domestic innovative targeted drug in the field of precision therapy for lung cancer in China.
Garsorasib, as the second KRAS G12C inhibitor approved in China, occupies an important position in the underserved niche market of KRAS G12C-mutant non-small cell lung cancer, relying on the strong commercialization capability of Chia Tai Tianqing. With its inclusion in medical insurance and the successive launch of multiple domestic similar drugs (Fuzolasib, Golorasib, Jilemei), the market has shifted from an early 'blue ocean' to a fiercely competitive stage. Its core advantages lie in domestic innovation, definite efficacy and favorable safety. In addition, price reduction through medical insurance negotiations has rapidly improved patient accessibility. In the future, market competition will focus on price, medical insurance coverage, clinical efficacy, combination therapy, indication expansion (such as colorectal cancer) and commercial channels. Relying on its first-mover advantage, medical insurance coverage and strong channels, Garsorasib is expected to maintain a stable share among similar domestic products, while facing challenges including price wars, medical insurance cost control and intensified competition from rival drugs.
This report is a detailed and comprehensive analysis for global Gesagliflozin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Gesagliflozin market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Gesagliflozin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Gesagliflozin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Gesagliflozin, with price, sales quantity, revenue, and global market share of Gesagliflozin from 2021 to 2026.
Chapter 3, the Gesagliflozin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gesagliflozin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Gesagliflozin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Gesagliflozin.
Chapter 14 and 15, to describe Gesagliflozin sales channel, distributors, customers, research findings and conclusion.
In 2025, global Garsorasib production reached approximately 5000 units.Garsorasib Tablets (generic name: Garsorasib Tablets, trade name: Anfangning) is an independently developed oral small-molecule targeted antineoplastic drug in China for the treatment of KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), belonging to irreversible KRAS G12C inhibitors. Its mechanism of action is to specifically bind and lock the inactive conformation of the mutant KRAS protein, block the abnormal activation of the downstream MAPK signaling pathway, thereby inhibiting tumor cell proliferation and inducing tumor cell apoptosis. This product is a 200 mg yellow oval film-coated tablet, approved for marketing in China in November 2024. It is mainly indicated for adult patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have received at least one prior systemic therapy. It serves as an important domestic innovative targeted drug in the field of precision therapy for lung cancer in China.
Garsorasib, as the second KRAS G12C inhibitor approved in China, occupies an important position in the underserved niche market of KRAS G12C-mutant non-small cell lung cancer, relying on the strong commercialization capability of Chia Tai Tianqing. With its inclusion in medical insurance and the successive launch of multiple domestic similar drugs (Fuzolasib, Golorasib, Jilemei), the market has shifted from an early 'blue ocean' to a fiercely competitive stage. Its core advantages lie in domestic innovation, definite efficacy and favorable safety. In addition, price reduction through medical insurance negotiations has rapidly improved patient accessibility. In the future, market competition will focus on price, medical insurance coverage, clinical efficacy, combination therapy, indication expansion (such as colorectal cancer) and commercial channels. Relying on its first-mover advantage, medical insurance coverage and strong channels, Garsorasib is expected to maintain a stable share among similar domestic products, while facing challenges including price wars, medical insurance cost control and intensified competition from rival drugs.
This report is a detailed and comprehensive analysis for global Gesagliflozin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Gesagliflozin market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Gesagliflozin market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Gesagliflozin
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Gesagliflozin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- 100mg
- 200mg
- Garsorasib and Immune Checkpoint Inhibitors
- Garsorasib and FAK Inhibitors
- Innovator
- Generic
- Hospital
- Retail
- Online
- KRAS G12C-Mutant Tumors
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer
- Pancreatic Cancer
- Others
- InventisBio
- Shanghai Chia Tai Tianqing Pharmaceutical
- WuXi AppTec Pharmaceutical
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Gesagliflozin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Gesagliflozin, with price, sales quantity, revenue, and global market share of Gesagliflozin from 2021 to 2026.
Chapter 3, the Gesagliflozin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gesagliflozin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Gesagliflozin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Gesagliflozin.
Chapter 14 and 15, to describe Gesagliflozin sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Gesagliflozin Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 100mg
1.3.3 200mg
1.4 Market Analysis by Combination Therapy
1.4.1 Overview: Global Gesagliflozin Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
1.4.2 Garsorasib and Immune Checkpoint Inhibitors
1.4.3 Garsorasib and FAK Inhibitors
1.5 Market Analysis by Production Technology
1.5.1 Overview: Global Gesagliflozin Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
1.5.2 Innovator
1.5.3 Generic
1.6 Market Analysis by Sales Channels
1.6.1 Overview: Global Gesagliflozin Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.6.2 Hospital
1.6.3 Retail
1.6.4 Online
1.7 Market Analysis by Application
1.7.1 Overview: Global Gesagliflozin Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 KRAS G12C-Mutant Tumors
1.7.3 Non-Small Cell Lung Cancer (NSCLC)
1.7.4 Colorectal Cancer
1.7.5 Pancreatic Cancer
1.7.6 Others
1.8 Global Gesagliflozin Market Size & Forecast
1.8.1 Global Gesagliflozin Consumption Value (2021 & 2025 & 2032)
1.8.2 Global Gesagliflozin Sales Quantity (2021-2032)
1.8.3 Global Gesagliflozin Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 InventisBio
2.1.1 InventisBio Details
2.1.2 InventisBio Major Business
2.1.3 InventisBio Gesagliflozin Product and Services
2.1.4 InventisBio Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 InventisBio Recent Developments/Updates
2.2 Shanghai Chia Tai Tianqing Pharmaceutical
2.2.1 Shanghai Chia Tai Tianqing Pharmaceutical Details
2.2.2 Shanghai Chia Tai Tianqing Pharmaceutical Major Business
2.2.3 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product and Services
2.2.4 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Shanghai Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
2.3 WuXi AppTec Pharmaceutical
2.3.1 WuXi AppTec Pharmaceutical Details
2.3.2 WuXi AppTec Pharmaceutical Major Business
2.3.3 WuXi AppTec Pharmaceutical Gesagliflozin Product and Services
2.3.4 WuXi AppTec Pharmaceutical Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 WuXi AppTec Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: GESAGLIFLOZIN BY MANUFACTURER
3.1 Global Gesagliflozin Sales Quantity by Manufacturer (2021-2026)
3.2 Global Gesagliflozin Revenue by Manufacturer (2021-2026)
3.3 Global Gesagliflozin Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Gesagliflozin by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Gesagliflozin Manufacturer Market Share in 2025
3.4.3 Top 6 Gesagliflozin Manufacturer Market Share in 2025
3.5 Gesagliflozin Market: Overall Company Footprint Analysis
3.5.1 Gesagliflozin Market: Region Footprint
3.5.2 Gesagliflozin Market: Company Product Type Footprint
3.5.3 Gesagliflozin Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Gesagliflozin Market Size by Region
4.1.1 Global Gesagliflozin Sales Quantity by Region (2021-2032)
4.1.2 Global Gesagliflozin Consumption Value by Region (2021-2032)
4.1.3 Global Gesagliflozin Average Price by Region (2021-2032)
4.2 North America Gesagliflozin Consumption Value (2021-2032)
4.3 Europe Gesagliflozin Consumption Value (2021-2032)
4.4 Asia-Pacific Gesagliflozin Consumption Value (2021-2032)
4.5 South America Gesagliflozin Consumption Value (2021-2032)
4.6 Middle East & Africa Gesagliflozin Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Gesagliflozin Sales Quantity by Type (2021-2032)
5.2 Global Gesagliflozin Consumption Value by Type (2021-2032)
5.3 Global Gesagliflozin Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Gesagliflozin Sales Quantity by Application (2021-2032)
6.2 Global Gesagliflozin Consumption Value by Application (2021-2032)
6.3 Global Gesagliflozin Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Gesagliflozin Sales Quantity by Type (2021-2032)
7.2 North America Gesagliflozin Sales Quantity by Application (2021-2032)
7.3 North America Gesagliflozin Market Size by Country
7.3.1 North America Gesagliflozin Sales Quantity by Country (2021-2032)
7.3.2 North America Gesagliflozin Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Gesagliflozin Sales Quantity by Type (2021-2032)
8.2 Europe Gesagliflozin Sales Quantity by Application (2021-2032)
8.3 Europe Gesagliflozin Market Size by Country
8.3.1 Europe Gesagliflozin Sales Quantity by Country (2021-2032)
8.3.2 Europe Gesagliflozin Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Gesagliflozin Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Gesagliflozin Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Gesagliflozin Market Size by Region
9.3.1 Asia-Pacific Gesagliflozin Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Gesagliflozin Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Gesagliflozin Sales Quantity by Type (2021-2032)
10.2 South America Gesagliflozin Sales Quantity by Application (2021-2032)
10.3 South America Gesagliflozin Market Size by Country
10.3.1 South America Gesagliflozin Sales Quantity by Country (2021-2032)
10.3.2 South America Gesagliflozin Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Gesagliflozin Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Gesagliflozin Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Gesagliflozin Market Size by Country
11.3.1 Middle East & Africa Gesagliflozin Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Gesagliflozin Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Gesagliflozin Market Drivers
12.2 Gesagliflozin Market Restraints
12.3 Gesagliflozin Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Gesagliflozin and Key Manufacturers
13.2 Manufacturing Costs Percentage of Gesagliflozin
13.3 Gesagliflozin Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Gesagliflozin Typical Distributors
14.3 Gesagliflozin Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Gesagliflozin Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 100mg
1.3.3 200mg
1.4 Market Analysis by Combination Therapy
1.4.1 Overview: Global Gesagliflozin Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
1.4.2 Garsorasib and Immune Checkpoint Inhibitors
1.4.3 Garsorasib and FAK Inhibitors
1.5 Market Analysis by Production Technology
1.5.1 Overview: Global Gesagliflozin Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
1.5.2 Innovator
1.5.3 Generic
1.6 Market Analysis by Sales Channels
1.6.1 Overview: Global Gesagliflozin Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
1.6.2 Hospital
1.6.3 Retail
1.6.4 Online
1.7 Market Analysis by Application
1.7.1 Overview: Global Gesagliflozin Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 KRAS G12C-Mutant Tumors
1.7.3 Non-Small Cell Lung Cancer (NSCLC)
1.7.4 Colorectal Cancer
1.7.5 Pancreatic Cancer
1.7.6 Others
1.8 Global Gesagliflozin Market Size & Forecast
1.8.1 Global Gesagliflozin Consumption Value (2021 & 2025 & 2032)
1.8.2 Global Gesagliflozin Sales Quantity (2021-2032)
1.8.3 Global Gesagliflozin Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 InventisBio
2.1.1 InventisBio Details
2.1.2 InventisBio Major Business
2.1.3 InventisBio Gesagliflozin Product and Services
2.1.4 InventisBio Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 InventisBio Recent Developments/Updates
2.2 Shanghai Chia Tai Tianqing Pharmaceutical
2.2.1 Shanghai Chia Tai Tianqing Pharmaceutical Details
2.2.2 Shanghai Chia Tai Tianqing Pharmaceutical Major Business
2.2.3 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product and Services
2.2.4 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Shanghai Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
2.3 WuXi AppTec Pharmaceutical
2.3.1 WuXi AppTec Pharmaceutical Details
2.3.2 WuXi AppTec Pharmaceutical Major Business
2.3.3 WuXi AppTec Pharmaceutical Gesagliflozin Product and Services
2.3.4 WuXi AppTec Pharmaceutical Gesagliflozin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 WuXi AppTec Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: GESAGLIFLOZIN BY MANUFACTURER
3.1 Global Gesagliflozin Sales Quantity by Manufacturer (2021-2026)
3.2 Global Gesagliflozin Revenue by Manufacturer (2021-2026)
3.3 Global Gesagliflozin Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Gesagliflozin by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Gesagliflozin Manufacturer Market Share in 2025
3.4.3 Top 6 Gesagliflozin Manufacturer Market Share in 2025
3.5 Gesagliflozin Market: Overall Company Footprint Analysis
3.5.1 Gesagliflozin Market: Region Footprint
3.5.2 Gesagliflozin Market: Company Product Type Footprint
3.5.3 Gesagliflozin Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Gesagliflozin Market Size by Region
4.1.1 Global Gesagliflozin Sales Quantity by Region (2021-2032)
4.1.2 Global Gesagliflozin Consumption Value by Region (2021-2032)
4.1.3 Global Gesagliflozin Average Price by Region (2021-2032)
4.2 North America Gesagliflozin Consumption Value (2021-2032)
4.3 Europe Gesagliflozin Consumption Value (2021-2032)
4.4 Asia-Pacific Gesagliflozin Consumption Value (2021-2032)
4.5 South America Gesagliflozin Consumption Value (2021-2032)
4.6 Middle East & Africa Gesagliflozin Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Gesagliflozin Sales Quantity by Type (2021-2032)
5.2 Global Gesagliflozin Consumption Value by Type (2021-2032)
5.3 Global Gesagliflozin Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Gesagliflozin Sales Quantity by Application (2021-2032)
6.2 Global Gesagliflozin Consumption Value by Application (2021-2032)
6.3 Global Gesagliflozin Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Gesagliflozin Sales Quantity by Type (2021-2032)
7.2 North America Gesagliflozin Sales Quantity by Application (2021-2032)
7.3 North America Gesagliflozin Market Size by Country
7.3.1 North America Gesagliflozin Sales Quantity by Country (2021-2032)
7.3.2 North America Gesagliflozin Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Gesagliflozin Sales Quantity by Type (2021-2032)
8.2 Europe Gesagliflozin Sales Quantity by Application (2021-2032)
8.3 Europe Gesagliflozin Market Size by Country
8.3.1 Europe Gesagliflozin Sales Quantity by Country (2021-2032)
8.3.2 Europe Gesagliflozin Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Gesagliflozin Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Gesagliflozin Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Gesagliflozin Market Size by Region
9.3.1 Asia-Pacific Gesagliflozin Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Gesagliflozin Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Gesagliflozin Sales Quantity by Type (2021-2032)
10.2 South America Gesagliflozin Sales Quantity by Application (2021-2032)
10.3 South America Gesagliflozin Market Size by Country
10.3.1 South America Gesagliflozin Sales Quantity by Country (2021-2032)
10.3.2 South America Gesagliflozin Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Gesagliflozin Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Gesagliflozin Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Gesagliflozin Market Size by Country
11.3.1 Middle East & Africa Gesagliflozin Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Gesagliflozin Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Gesagliflozin Market Drivers
12.2 Gesagliflozin Market Restraints
12.3 Gesagliflozin Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Gesagliflozin and Key Manufacturers
13.2 Manufacturing Costs Percentage of Gesagliflozin
13.3 Gesagliflozin Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Gesagliflozin Typical Distributors
14.3 Gesagliflozin Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Gesagliflozin Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Gesagliflozin Consumption Value by Combination Therapy, (USD Million), 2021 & 2025 & 2032
Table 3. Global Gesagliflozin Consumption Value by Production Technology, (USD Million), 2021 & 2025 & 2032
Table 4. Global Gesagliflozin Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 5. Global Gesagliflozin Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. InventisBio Basic Information, Manufacturing Base and Competitors
Table 7. InventisBio Major Business
Table 8. InventisBio Gesagliflozin Product and Services
Table 9. InventisBio Gesagliflozin Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. InventisBio Recent Developments/Updates
Table 11. Shanghai Chia Tai Tianqing Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 12. Shanghai Chia Tai Tianqing Pharmaceutical Major Business
Table 13. Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product and Services
Table 14. Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 15. Shanghai Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 16. WuXi AppTec Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 17. WuXi AppTec Pharmaceutical Major Business
Table 18. WuXi AppTec Pharmaceutical Gesagliflozin Product and Services
Table 19. WuXi AppTec Pharmaceutical Gesagliflozin Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 20. WuXi AppTec Pharmaceutical Recent Developments/Updates
Table 21. Global Gesagliflozin Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 22. Global Gesagliflozin Revenue by Manufacturer (2021-2026) & (USD Million)
Table 23. Global Gesagliflozin Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 24. Market Position of Manufacturers in Gesagliflozin, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 25. Head Office and Gesagliflozin Production Site of Key Manufacturer
Table 26. Gesagliflozin Market: Company Product Type Footprint
Table 27. Gesagliflozin Market: Company Product Application Footprint
Table 28. Gesagliflozin New Market Entrants and Barriers to Market Entry
Table 29. Gesagliflozin Mergers, Acquisition, Agreements, and Collaborations
Table 30. Global Gesagliflozin Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 31. Global Gesagliflozin Sales Quantity by Region (2021-2026) & (Units)
Table 32. Global Gesagliflozin Sales Quantity by Region (2027-2032) & (Units)
Table 33. Global Gesagliflozin Consumption Value by Region (2021-2026) & (USD Million)
Table 34. Global Gesagliflozin Consumption Value by Region (2027-2032) & (USD Million)
Table 35. Global Gesagliflozin Average Price by Region (2021-2026) & (US$/Unit)
Table 36. Global Gesagliflozin Average Price by Region (2027-2032) & (US$/Unit)
Table 37. Global Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 38. Global Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 39. Global Gesagliflozin Consumption Value by Type (2021-2026) & (USD Million)
Table 40. Global Gesagliflozin Consumption Value by Type (2027-2032) & (USD Million)
Table 41. Global Gesagliflozin Average Price by Type (2021-2026) & (US$/Unit)
Table 42. Global Gesagliflozin Average Price by Type (2027-2032) & (US$/Unit)
Table 43. Global Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 44. Global Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 45. Global Gesagliflozin Consumption Value by Application (2021-2026) & (USD Million)
Table 46. Global Gesagliflozin Consumption Value by Application (2027-2032) & (USD Million)
Table 47. Global Gesagliflozin Average Price by Application (2021-2026) & (US$/Unit)
Table 48. Global Gesagliflozin Average Price by Application (2027-2032) & (US$/Unit)
Table 49. North America Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 50. North America Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 51. North America Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 52. North America Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 53. North America Gesagliflozin Sales Quantity by Country (2021-2026) & (Units)
Table 54. North America Gesagliflozin Sales Quantity by Country (2027-2032) & (Units)
Table 55. North America Gesagliflozin Consumption Value by Country (2021-2026) & (USD Million)
Table 56. North America Gesagliflozin Consumption Value by Country (2027-2032) & (USD Million)
Table 57. Europe Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 58. Europe Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 59. Europe Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 60. Europe Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 61. Europe Gesagliflozin Sales Quantity by Country (2021-2026) & (Units)
Table 62. Europe Gesagliflozin Sales Quantity by Country (2027-2032) & (Units)
Table 63. Europe Gesagliflozin Consumption Value by Country (2021-2026) & (USD Million)
Table 64. Europe Gesagliflozin Consumption Value by Country (2027-2032) & (USD Million)
Table 65. Asia-Pacific Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 66. Asia-Pacific Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 67. Asia-Pacific Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 68. Asia-Pacific Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 69. Asia-Pacific Gesagliflozin Sales Quantity by Region (2021-2026) & (Units)
Table 70. Asia-Pacific Gesagliflozin Sales Quantity by Region (2027-2032) & (Units)
Table 71. Asia-Pacific Gesagliflozin Consumption Value by Region (2021-2026) & (USD Million)
Table 72. Asia-Pacific Gesagliflozin Consumption Value by Region (2027-2032) & (USD Million)
Table 73. South America Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 74. South America Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 75. South America Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 76. South America Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 77. South America Gesagliflozin Sales Quantity by Country (2021-2026) & (Units)
Table 78. South America Gesagliflozin Sales Quantity by Country (2027-2032) & (Units)
Table 79. South America Gesagliflozin Consumption Value by Country (2021-2026) & (USD Million)
Table 80. South America Gesagliflozin Consumption Value by Country (2027-2032) & (USD Million)
Table 81. Middle East & Africa Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 82. Middle East & Africa Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 83. Middle East & Africa Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 84. Middle East & Africa Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 85. Middle East & Africa Gesagliflozin Sales Quantity by Country (2021-2026) & (Units)
Table 86. Middle East & Africa Gesagliflozin Sales Quantity by Country (2027-2032) & (Units)
Table 87. Middle East & Africa Gesagliflozin Consumption Value by Country (2021-2026) & (USD Million)
Table 88. Middle East & Africa Gesagliflozin Consumption Value by Country (2027-2032) & (USD Million)
Table 89. Gesagliflozin Raw Material
Table 90. Key Manufacturers of Gesagliflozin Raw Materials
Table 91. Gesagliflozin Typical Distributors
Table 92. Gesagliflozin Typical Customers
Table 1. Global Gesagliflozin Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Gesagliflozin Consumption Value by Combination Therapy, (USD Million), 2021 & 2025 & 2032
Table 3. Global Gesagliflozin Consumption Value by Production Technology, (USD Million), 2021 & 2025 & 2032
Table 4. Global Gesagliflozin Consumption Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 5. Global Gesagliflozin Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. InventisBio Basic Information, Manufacturing Base and Competitors
Table 7. InventisBio Major Business
Table 8. InventisBio Gesagliflozin Product and Services
Table 9. InventisBio Gesagliflozin Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. InventisBio Recent Developments/Updates
Table 11. Shanghai Chia Tai Tianqing Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 12. Shanghai Chia Tai Tianqing Pharmaceutical Major Business
Table 13. Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product and Services
Table 14. Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 15. Shanghai Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 16. WuXi AppTec Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 17. WuXi AppTec Pharmaceutical Major Business
Table 18. WuXi AppTec Pharmaceutical Gesagliflozin Product and Services
Table 19. WuXi AppTec Pharmaceutical Gesagliflozin Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 20. WuXi AppTec Pharmaceutical Recent Developments/Updates
Table 21. Global Gesagliflozin Sales Quantity by Manufacturer (2021-2026) & (Units)
Table 22. Global Gesagliflozin Revenue by Manufacturer (2021-2026) & (USD Million)
Table 23. Global Gesagliflozin Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 24. Market Position of Manufacturers in Gesagliflozin, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 25. Head Office and Gesagliflozin Production Site of Key Manufacturer
Table 26. Gesagliflozin Market: Company Product Type Footprint
Table 27. Gesagliflozin Market: Company Product Application Footprint
Table 28. Gesagliflozin New Market Entrants and Barriers to Market Entry
Table 29. Gesagliflozin Mergers, Acquisition, Agreements, and Collaborations
Table 30. Global Gesagliflozin Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 31. Global Gesagliflozin Sales Quantity by Region (2021-2026) & (Units)
Table 32. Global Gesagliflozin Sales Quantity by Region (2027-2032) & (Units)
Table 33. Global Gesagliflozin Consumption Value by Region (2021-2026) & (USD Million)
Table 34. Global Gesagliflozin Consumption Value by Region (2027-2032) & (USD Million)
Table 35. Global Gesagliflozin Average Price by Region (2021-2026) & (US$/Unit)
Table 36. Global Gesagliflozin Average Price by Region (2027-2032) & (US$/Unit)
Table 37. Global Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 38. Global Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 39. Global Gesagliflozin Consumption Value by Type (2021-2026) & (USD Million)
Table 40. Global Gesagliflozin Consumption Value by Type (2027-2032) & (USD Million)
Table 41. Global Gesagliflozin Average Price by Type (2021-2026) & (US$/Unit)
Table 42. Global Gesagliflozin Average Price by Type (2027-2032) & (US$/Unit)
Table 43. Global Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 44. Global Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 45. Global Gesagliflozin Consumption Value by Application (2021-2026) & (USD Million)
Table 46. Global Gesagliflozin Consumption Value by Application (2027-2032) & (USD Million)
Table 47. Global Gesagliflozin Average Price by Application (2021-2026) & (US$/Unit)
Table 48. Global Gesagliflozin Average Price by Application (2027-2032) & (US$/Unit)
Table 49. North America Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 50. North America Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 51. North America Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 52. North America Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 53. North America Gesagliflozin Sales Quantity by Country (2021-2026) & (Units)
Table 54. North America Gesagliflozin Sales Quantity by Country (2027-2032) & (Units)
Table 55. North America Gesagliflozin Consumption Value by Country (2021-2026) & (USD Million)
Table 56. North America Gesagliflozin Consumption Value by Country (2027-2032) & (USD Million)
Table 57. Europe Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 58. Europe Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 59. Europe Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 60. Europe Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 61. Europe Gesagliflozin Sales Quantity by Country (2021-2026) & (Units)
Table 62. Europe Gesagliflozin Sales Quantity by Country (2027-2032) & (Units)
Table 63. Europe Gesagliflozin Consumption Value by Country (2021-2026) & (USD Million)
Table 64. Europe Gesagliflozin Consumption Value by Country (2027-2032) & (USD Million)
Table 65. Asia-Pacific Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 66. Asia-Pacific Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 67. Asia-Pacific Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 68. Asia-Pacific Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 69. Asia-Pacific Gesagliflozin Sales Quantity by Region (2021-2026) & (Units)
Table 70. Asia-Pacific Gesagliflozin Sales Quantity by Region (2027-2032) & (Units)
Table 71. Asia-Pacific Gesagliflozin Consumption Value by Region (2021-2026) & (USD Million)
Table 72. Asia-Pacific Gesagliflozin Consumption Value by Region (2027-2032) & (USD Million)
Table 73. South America Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 74. South America Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 75. South America Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 76. South America Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 77. South America Gesagliflozin Sales Quantity by Country (2021-2026) & (Units)
Table 78. South America Gesagliflozin Sales Quantity by Country (2027-2032) & (Units)
Table 79. South America Gesagliflozin Consumption Value by Country (2021-2026) & (USD Million)
Table 80. South America Gesagliflozin Consumption Value by Country (2027-2032) & (USD Million)
Table 81. Middle East & Africa Gesagliflozin Sales Quantity by Type (2021-2026) & (Units)
Table 82. Middle East & Africa Gesagliflozin Sales Quantity by Type (2027-2032) & (Units)
Table 83. Middle East & Africa Gesagliflozin Sales Quantity by Application (2021-2026) & (Units)
Table 84. Middle East & Africa Gesagliflozin Sales Quantity by Application (2027-2032) & (Units)
Table 85. Middle East & Africa Gesagliflozin Sales Quantity by Country (2021-2026) & (Units)
Table 86. Middle East & Africa Gesagliflozin Sales Quantity by Country (2027-2032) & (Units)
Table 87. Middle East & Africa Gesagliflozin Consumption Value by Country (2021-2026) & (USD Million)
Table 88. Middle East & Africa Gesagliflozin Consumption Value by Country (2027-2032) & (USD Million)
Table 89. Gesagliflozin Raw Material
Table 90. Key Manufacturers of Gesagliflozin Raw Materials
Table 91. Gesagliflozin Typical Distributors
Table 92. Gesagliflozin Typical Customers
LIST OF FIGURES
Figure 1. Gesagliflozin Picture
Figure 2. Global Gesagliflozin Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Gesagliflozin Revenue Market Share by Type in 2025
Figure 4. 100mg Examples
Figure 5. 200mg Examples
Figure 6. Global Gesagliflozin Revenue by Combination Therapy, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Gesagliflozin Revenue Market Share by Combination Therapy in 2025
Figure 8. Garsorasib and Immune Checkpoint Inhibitors Examples
Figure 9. Garsorasib and FAK Inhibitors Examples
Figure 10. Global Gesagliflozin Revenue by Production Technology, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Gesagliflozin Revenue Market Share by Production Technology in 2025
Figure 12. Innovator Examples
Figure 13. Generic Examples
Figure 14. Global Gesagliflozin Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Gesagliflozin Revenue Market Share by Sales Channels in 2025
Figure 16. Hospital Examples
Figure 17. Retail Examples
Figure 18. Online Examples
Figure 19. Global Gesagliflozin Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 20. Global Gesagliflozin Revenue Market Share by Application in 2025
Figure 21. KRAS G12C-Mutant Tumors Examples
Figure 22. Non-Small Cell Lung Cancer (NSCLC) Examples
Figure 23. Colorectal Cancer Examples
Figure 24. Pancreatic Cancer Examples
Figure 25. Others Examples
Figure 26. Global Gesagliflozin Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 27. Global Gesagliflozin Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 28. Global Gesagliflozin Sales Quantity (2021-2032) & (Units)
Figure 29. Global Gesagliflozin Price (2021-2032) & (US$/Unit)
Figure 30. Global Gesagliflozin Sales Quantity Market Share by Manufacturer in 2025
Figure 31. Global Gesagliflozin Revenue Market Share by Manufacturer in 2025
Figure 32. Producer Shipments of Gesagliflozin by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 33. Top 3 Gesagliflozin Manufacturer (Revenue) Market Share in 2025
Figure 34. Top 6 Gesagliflozin Manufacturer (Revenue) Market Share in 2025
Figure 35. Global Gesagliflozin Sales Quantity Market Share by Region (2021-2032)
Figure 36. Global Gesagliflozin Consumption Value Market Share by Region (2021-2032)
Figure 37. North America Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 39. Asia-Pacific Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 40. South America Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 41. Middle East & Africa Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 42. Global Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 43. Global Gesagliflozin Consumption Value Market Share by Type (2021-2032)
Figure 44. Global Gesagliflozin Average Price by Type (2021-2032) & (US$/Unit)
Figure 45. Global Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 46. Global Gesagliflozin Revenue Market Share by Application (2021-2032)
Figure 47. Global Gesagliflozin Average Price by Application (2021-2032) & (US$/Unit)
Figure 48. North America Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 49. North America Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 50. North America Gesagliflozin Sales Quantity Market Share by Country (2021-2032)
Figure 51. North America Gesagliflozin Consumption Value Market Share by Country (2021-2032)
Figure 52. United States Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 53. Canada Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 54. Mexico Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 55. Europe Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 56. Europe Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 57. Europe Gesagliflozin Sales Quantity Market Share by Country (2021-2032)
Figure 58. Europe Gesagliflozin Consumption Value Market Share by Country (2021-2032)
Figure 59. Germany Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 60. France Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 61. United Kingdom Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 62. Russia Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 63. Italy Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 64. Asia-Pacific Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 65. Asia-Pacific Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 66. Asia-Pacific Gesagliflozin Sales Quantity Market Share by Region (2021-2032)
Figure 67. Asia-Pacific Gesagliflozin Consumption Value Market Share by Region (2021-2032)
Figure 68. China Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 69. Japan Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 70. South Korea Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 71. India Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 72. Southeast Asia Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 73. Australia Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 74. South America Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 75. South America Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 76. South America Gesagliflozin Sales Quantity Market Share by Country (2021-2032)
Figure 77. South America Gesagliflozin Consumption Value Market Share by Country (2021-2032)
Figure 78. Brazil Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 79. Argentina Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 80. Middle East & Africa Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 81. Middle East & Africa Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 82. Middle East & Africa Gesagliflozin Sales Quantity Market Share by Country (2021-2032)
Figure 83. Middle East & Africa Gesagliflozin Consumption Value Market Share by Country (2021-2032)
Figure 84. Turkey Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 85. Egypt Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 86. Saudi Arabia Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 87. South Africa Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 88. Gesagliflozin Market Drivers
Figure 89. Gesagliflozin Market Restraints
Figure 90. Gesagliflozin Market Trends
Figure 91. Porters Five Forces Analysis
Figure 92. Manufacturing Cost Structure Analysis of Gesagliflozin in 2025
Figure 93. Manufacturing Process Analysis of Gesagliflozin
Figure 94. Gesagliflozin Industrial Chain
Figure 95. Sales Channel: Direct to End-User vs Distributors
Figure 96. Direct Channel Pros & Cons
Figure 97. Indirect Channel Pros & Cons
Figure 98. Methodology
Figure 99. Research Process and Data Source
Figure 1. Gesagliflozin Picture
Figure 2. Global Gesagliflozin Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Gesagliflozin Revenue Market Share by Type in 2025
Figure 4. 100mg Examples
Figure 5. 200mg Examples
Figure 6. Global Gesagliflozin Revenue by Combination Therapy, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Gesagliflozin Revenue Market Share by Combination Therapy in 2025
Figure 8. Garsorasib and Immune Checkpoint Inhibitors Examples
Figure 9. Garsorasib and FAK Inhibitors Examples
Figure 10. Global Gesagliflozin Revenue by Production Technology, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Gesagliflozin Revenue Market Share by Production Technology in 2025
Figure 12. Innovator Examples
Figure 13. Generic Examples
Figure 14. Global Gesagliflozin Revenue by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Gesagliflozin Revenue Market Share by Sales Channels in 2025
Figure 16. Hospital Examples
Figure 17. Retail Examples
Figure 18. Online Examples
Figure 19. Global Gesagliflozin Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 20. Global Gesagliflozin Revenue Market Share by Application in 2025
Figure 21. KRAS G12C-Mutant Tumors Examples
Figure 22. Non-Small Cell Lung Cancer (NSCLC) Examples
Figure 23. Colorectal Cancer Examples
Figure 24. Pancreatic Cancer Examples
Figure 25. Others Examples
Figure 26. Global Gesagliflozin Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 27. Global Gesagliflozin Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 28. Global Gesagliflozin Sales Quantity (2021-2032) & (Units)
Figure 29. Global Gesagliflozin Price (2021-2032) & (US$/Unit)
Figure 30. Global Gesagliflozin Sales Quantity Market Share by Manufacturer in 2025
Figure 31. Global Gesagliflozin Revenue Market Share by Manufacturer in 2025
Figure 32. Producer Shipments of Gesagliflozin by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 33. Top 3 Gesagliflozin Manufacturer (Revenue) Market Share in 2025
Figure 34. Top 6 Gesagliflozin Manufacturer (Revenue) Market Share in 2025
Figure 35. Global Gesagliflozin Sales Quantity Market Share by Region (2021-2032)
Figure 36. Global Gesagliflozin Consumption Value Market Share by Region (2021-2032)
Figure 37. North America Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 39. Asia-Pacific Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 40. South America Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 41. Middle East & Africa Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 42. Global Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 43. Global Gesagliflozin Consumption Value Market Share by Type (2021-2032)
Figure 44. Global Gesagliflozin Average Price by Type (2021-2032) & (US$/Unit)
Figure 45. Global Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 46. Global Gesagliflozin Revenue Market Share by Application (2021-2032)
Figure 47. Global Gesagliflozin Average Price by Application (2021-2032) & (US$/Unit)
Figure 48. North America Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 49. North America Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 50. North America Gesagliflozin Sales Quantity Market Share by Country (2021-2032)
Figure 51. North America Gesagliflozin Consumption Value Market Share by Country (2021-2032)
Figure 52. United States Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 53. Canada Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 54. Mexico Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 55. Europe Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 56. Europe Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 57. Europe Gesagliflozin Sales Quantity Market Share by Country (2021-2032)
Figure 58. Europe Gesagliflozin Consumption Value Market Share by Country (2021-2032)
Figure 59. Germany Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 60. France Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 61. United Kingdom Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 62. Russia Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 63. Italy Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 64. Asia-Pacific Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 65. Asia-Pacific Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 66. Asia-Pacific Gesagliflozin Sales Quantity Market Share by Region (2021-2032)
Figure 67. Asia-Pacific Gesagliflozin Consumption Value Market Share by Region (2021-2032)
Figure 68. China Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 69. Japan Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 70. South Korea Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 71. India Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 72. Southeast Asia Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 73. Australia Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 74. South America Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 75. South America Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 76. South America Gesagliflozin Sales Quantity Market Share by Country (2021-2032)
Figure 77. South America Gesagliflozin Consumption Value Market Share by Country (2021-2032)
Figure 78. Brazil Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 79. Argentina Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 80. Middle East & Africa Gesagliflozin Sales Quantity Market Share by Type (2021-2032)
Figure 81. Middle East & Africa Gesagliflozin Sales Quantity Market Share by Application (2021-2032)
Figure 82. Middle East & Africa Gesagliflozin Sales Quantity Market Share by Country (2021-2032)
Figure 83. Middle East & Africa Gesagliflozin Consumption Value Market Share by Country (2021-2032)
Figure 84. Turkey Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 85. Egypt Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 86. Saudi Arabia Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 87. South Africa Gesagliflozin Consumption Value (2021-2032) & (USD Million)
Figure 88. Gesagliflozin Market Drivers
Figure 89. Gesagliflozin Market Restraints
Figure 90. Gesagliflozin Market Trends
Figure 91. Porters Five Forces Analysis
Figure 92. Manufacturing Cost Structure Analysis of Gesagliflozin in 2025
Figure 93. Manufacturing Process Analysis of Gesagliflozin
Figure 94. Gesagliflozin Industrial Chain
Figure 95. Sales Channel: Direct to End-User vs Distributors
Figure 96. Direct Channel Pros & Cons
Figure 97. Indirect Channel Pros & Cons
Figure 98. Methodology
Figure 99. Research Process and Data Source
